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OBJECTIVE: To determine which studies provide best evi-
dence of the cost effectiveness of drugs.
METHODS: During 1998, we found 1398 pharmacoeco-
nomic studies had been published in over 2300 medical
journals. We summarised and evaluated all of these using
an objective scoring system. The evaluation looked at study
design, its conduct, and the adequacy of the published re-
port. Points were awarded for key elements in trials (e.g.,
clear statement of aims of study and study perspective; va-
lidity of treatment alternatives; relevance of outcomes mea-
sured; clear statement of sources of cost and outcome data;
appropriate discounting used; accurate reporting and dis-
cussion of results, relevance of author’s conclusions; clini-
cal relevance of results. Points for each element were added
to give an overall score out of 100 for each study.
RESULTS: There were 101 studies that achieved a score

66%. Cardiovascular medicine featured in 28 of the 101
top studies, followed by cancer chemotherapy (12) respira-
tory medicine (11), antiviral therapy (11), vaccines (10),
antibacterial drug therapy (8) and neuropsychotherapeutics
(7). There were 40 of 101 studies from institutions based in
the USA. Canada produced 12 of the top studies followed
by, France (9), England (9), Italy (7), Germany (7), Sweden
(4), The Netherlands (4) and Australia (2). Glaxo Wellcome
supported 11 of the top studies followed by Bristol-Myers
Squibb, Eli Lilly, Pharmacia & Upjohn and Wyeth Ayerst
(3 each). The following journals are publishing the best-
designed pharmacoeconomic studies: Pharmacoeconomics
(17 studies); AIDS (6); Archives of Internal Medicine (3);
British Medical Journal (3); Circulation (3); Clinical Drug
Investigation (3); Journal of Clinical Oncology (3); Journal
of the American Medical Association (3); Vaccine (3).
CONCLUSION: This analysis provides valuable qualita-
tive and quantitative evidence of the extent and nature of
worldwide pharmacoeconomic publishing.
